Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
A study of 165 people with relapsing-remitting multiple sclerosis found that psychological resilience independently predicts better medication adherence to disease-modifying therapies, even after accounting for depression, anxiety, stress, quality of life, and disability level. Those with good adherence showed significantly higher resilience scores and lower psychological distress compared to poorly adherent patients.
This systematic review examines how multiple sclerosis is stratified into activity-based subgroups across clinical trials and regulatory guidance, identifying significant inconsistencies in terminology and definitions for 'active', 'highly active', and 'rapidly evolving severe' disease. The authors propose a standardized framework to improve consistency in treatment decision-making and health technology assessments.
This study re-evaluates the classical model that processing speed is the primary cognitive deficit in MS by examining patients diagnosed and treated in the modern era (2001-2025). Early relapsing-remitting MS patients showed memory deficits but normal cognitive speed, contradicting the traditional speed-centric model and suggesting disease-modifying therapies may have altered the cognitive profile of MS.
This cross-sectional study found that patients with relapsing-remitting MS have reduced cerebrovascular reactivity (measured by Breath-Holding Index) compared to healthy controls, independent of demographic factors. Lower cerebrovascular reactivity was independently associated with greater neurological disability and slower processing speed on cognitive testing.
A woman in her 50s with confirmed Huntington's disease developed right-sided sensory symptoms and was diagnosed with relapsing-remitting MS based on MRI findings of demyelinating lesions, oligoclonal bands in cerebrospinal fluid, and McDonald diagnostic criteria. The case underscores the importance of evaluating new neurological symptoms in patients with neurodegenerative conditions rather than attributing all manifestations to a single disease process.